Spatial transcriptomics of B cell targeting T-cell engager therapy reveals extrafollicular niche collapse and a pretreatment fibrogenic-stromal signature in multidrug-resistant RA (ACR Convergence 2026) - Sep 8, 2026 - Abstract #2027; Pres time: Nov 10, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; " Paired synovial biopsies from 4 patients with multidrug-resistant RA were obtained before and 29-147 days after low-dose TCE therapy (P1 mosunetuzumab; P2-P4 blinatumomab). Patients were refractory to multiple bDMARD/tsDMARDs, and 3 of 4 had been treated with rituximab... B-cell depletion via TCE potently extinguishes an extrafollicular, Tph-driven B/plasmablast program in RA synovium. Since B and plasma cells were depleted even in P4, poor clinical response may reflect a pre-existing stromal fibrogenic/inflammatory program. Pretreatment fibrogenic burden is a candidate spatial correlate of TCE refractoriness warranting prospective evaluation as a stratification biomarker."
IO biomarker • Stroma • Fibrosis • Immunology • Rheumatoid Arthritis • Rheumatology • CCL18 • CTHRC1 • CXCL13 • CXCR5 • ICOS • PD-1 • SFRP4
|
|
Futoshi Iwata1; Laura Bucci2; Maria Del Mar Muñiz Moreno3; Melanie Hagen2; Andreas Wirsching2; Carlo Tur2; Sebastian Boeltz4; Danae-Mona Noethling5; Jochen Wacker1; Aline Bozec2; Maria G. Raimondo6; Markus Eckstein7; Georg Schett6; Ricardo Grieshaber-Bouyer4
|